A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 127
Updated:3/14/2019
Start Date:March 16, 2018
End Date:September 28, 2021
Contact:AstraZeneca Clinical Study Information Center
Email:information.center@astrazeneca.com
Phone:1-877-240-9479

Use our guide to learn which trials are right for you!

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer

A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the
Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in
Platinum-Ineligible Patients With Unresectable Stage IV Urothelial Cancer

This is a Phase II, randomized, double-blind, placebo controlled, multi-center, comparative
global study to determine the efficacy and safety of durvalumab + olaparib combination
therapy versus durvalumab + placebo (durvalumab monotherapy) as first-line treatment in
patients ineligible for platinum-based chemotherapy with unresectable Stage IV urothelial
cancer (UC).

Inclusion criteria:

1. Provision of signed and dated, written ICF

2. Histologically or cytologically documented TCC/UC of the urothelium (including renal
pelvis, ureters, urinary bladder, and urethra) also meeting the following:
Unresectable, Stage IV disease; No prior systemic therapy for unresectable, Stage IV
disease.

3. Ineligible for platinum-based chemotherapy defined as (i) in the opinion of the
Investigator, unfit for carboplatin-based chemotherapy and (ii) meeting one of the
following criteria: CrCl <60 mL/min calculated by Cockcroft-Gault equation; Common
Terminology Criteria for Adverse Events (CTCAE) Grade ≥2 audiometric hearing loss (25
dB in 2 consecutive wave ranges); CTCAE Grade ≥2 peripheral neuropathy; New York Heart
Association Class III heart failure; ECOG 2.

4. Known tumor HRR mutation status prior to randomization.

5. World Health Organization (WHO)/ECOG performance status of 0, 1, or 2.

6. Patients with at least 1 RECIST 1.1 target lesion at baseline.

7. Ability to swallow oral medications.

8. Evidence of post-menopausal status, or negative urinary or serum pregnancy test for
female pre-menopausal patients.

Exclusion criteria

1. Active or prior documented autoimmune or inflammatory disorders.

2. Other invasive malignancy within 5 years before the first dose of the IP.

3. Major surgical procedure within 28 days prior to the first dose

4. Brain metastases or spinal cord compression unless the patient's condition is stable
and off steroid for at least 14 days

5. History of active primary immunodeficiency.

6. Active infection including tuberculosis (TB)

7. History of allogenic organ transplantation.

8. Uncontrolled intercurrent illness

9. Prior exposure to a PARP inhibitor or immune-mediated therapy.

10. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment.

11. Current or prior use of immunosuppressive medication within 14 days before the first
dose of the IP.

12. No radiation therapy is allowed, unless it is (1) definitive radiation that had been
administered at least 12 months prior; (2) palliative radiation to the brain, with
associated criteria for stability or lack of symptoms; or (3) palliative radiation to
painful bony lesions (this must comprise less than 30% of the bone marrow) or
symptomatic pelvic soft tissue mass(es).

13. Receipt of live attenuated vaccine within 30 days prior to the first dose of the IP.

14. Patients with a known hypersensitivity to durvalumab, olaparib, or any of the
excipients of the products.

15. Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ effective birth control from
screening to 90 days after the last dose of durvalumab.
We found this trial at
25
sites
?
mi
from
Stanford, CA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
?
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Fort Myers, FL
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Goodyear, AZ
Click here to add this to my saved trials
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newnan, GA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Saint Petersburg, Florida 33713
?
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Toronto,
Click here to add this to my saved trials
?
mi
from
Zion, IL
Click here to add this to my saved trials